Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma.
Jonathon W SenefeldPatrick W JohnsonKatie L KunzeNoud van HelmondStephen A KlassenChad C WigginsKatelyn A BrunoMichael A GolafsharMolly M PetersenMatthew R BurasAllan M KlompasMatthew A SextonJuan C Diaz SotoSarah E BakerJohn R A ShepherdNicole C VerdunPeter W MarksCamille M van BuskirkJeffrey Lawrence WintersJames R StubbsRobert F ReaVitaly HerasevichEmily R WhelanAndrew J ClayburnKathryn F LarsonJuan G RipollKylie J AndersenMatthew N P VogtJoshua J DennisRiley J RegimbalPhilippe R BauerJanis E BlairKatherine WrightJoel T GreenshieldsNigel S PanethDeLisa FairweatherR Scott WrightArturo CasadevallRickey E CarterMichael J JoynerPublished in: medRxiv : the preprint server for health sciences (2021)
The EAP successfully provided widespread access to COVID-19 convalescent plasma in all 50 states, including for underserved racial and ethnic minority populations. The efficient study design of the EAP may serve as an example framework for future efforts when broad access to a treatment is needed in response to a dynamic disease affecting demographic groups and areas historically underrepresented in clinical studies.